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INTRODUCTION
A new challenge in the HIV/AIDS epidemic in Western countries is an increase in infection rates among the older population. It is estimated that approximately 15-20% of HIV-1 infected people in the United States are 50 years of age or older (Shah and Mildvan, 2006) . This is partly caused by increased survival rates due to more effective antiretroviral therapy. In addition, the rates of new HIV-1 infections are rapidly growing in older people. Due to a variety of sociological, biological, and medical implications, this trend may further increase in the near future. These facts are of significant concerns because elderly patients develop AIDS more rapidly and have higher morbidity and mortality rates. In addition, older patients are more likely to develop HIV-associated dementia. This phenomenon appears not to be related to the length of HIV-1 infection (Valcour and Paul, 2006) , suggesting that aging can independently aggravate HIV-1 associated CNS pathology.
Among a variety of mechanisms which can be affected by HIV infection and aging, alterations of the blood-brain barrier (BBB) appear to be especially important. Even normal aging can lead to the BBB disturbances, including disrupted microvascular integrity, higher permeability to albumin, and accumulation and depositions of amyloid beta (Aβ) that precede neuronal degeneration and dementia (Price and Morris, 1999) . In addition, disturbances of the BBB are associated with HIV-1 infection and HIV-1 trafficking into the brain (for review see Persidsky and Poluektova, 2006) . and Geiger, 1998). In support of its pathogenic role, Tat was detected in the perivascular cells of AIDS patients with HIV-associated encephalitis (Gartner, 2000) . Tat can easily cross cell membranes and can affect brain endothelial cells, including stimulation of inflammatory responses and alterations of tight junction protein expression (for review see Toborek et al., 2005) . Interestingly, Tat can elevate Aβ levels in the CNS by inhibiting the Aβ-degrading enzyme, neprilysin (Rempel and Pulliam, 2005) . This phenomenon may have important implications for older HIV-infected patients. Indeed, HIV-1 infection and prolonged antiretroviral therapy were demonstrated to contribute to an increase in Aβ deposition in older HIVinfected individuals (Green et al., 2005) . In addition, Aβ levels in the CSF were shown to correlate with AIDS dementia complex (Brew et al., 2005) .
Aβ is the major constituent of senile plaques and cerebrovascular deposits. It is deposited in the brain parenchyma and cerebral blood vessels in normal aging and Alzheimer's disease (AD) . It was demonstrated that the BBB can regulate Aβ transport into the brain via two main receptors, the low density lipoprotein receptor related protein 1 (LRP1) and the receptor for advanced glycation end products (RAGE) (Deane and Zlokovic, 2007) . The main forms of Aβ are the 1-40 and 1-42 fragments originating from amyloid precursor protein (APP) by physiological proteolytic processes. Soluble Aβ(1-40) is present mainly in the circulation and in cerebral vascular amyloid. In contrast, Aβ(1-42) is mainly localized to the senile plaques (Seubert et al., 1992) . Exposure to Aβ can affect the metabolism of endothelial cells by several mechanisms, including induction of inflammatory responses (Paris et al., 2002; Toborek et al., 2005) . Aβ can also stimulate infection of target CD4 positive cells by HIV-1 (Wojtowicz et al., 2002) .
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MATERIALS AND METHODS
Cell cultures
Human brain microvascular endothelial cells (HBMEC): brain endothelial cells used in
the present study represent the first stable, fully characterized, and well-differentiated human brain endothelial cell line (Weksler et al., 2005) . HBMEC were cultured in EBM-2 medium (Clonetics, East Rutherford, NJ) supplemented with VEGF, IGF-1, EGF, basic FGF, hydrocortisone, ascorbate, gentamycin, and 2.5% fetal bovine serum (FBS) as originally described (Weksler et al., 2005) . Collagen type I (BD Biosciences Pharmingen, San Jose, CA) was used for coating the cell culture dishes.
Tat expressing astrocytes: SVGA cells, which represent a human astrocyte cell line, were stably transfected with Tat expression construct (SVGA-Tat cells) as described and characterized previously (Chauhan et al., 2007) . Control SVGA cells were transfected with an empty vector.
The cells were maintained in Dulbecco's Eagle Modified Medium (DMEM, Sigma, St. Louis, MO) supplemented with 10% heat inactivated FBS (Hyclone, Logan, UT), 100 U/ml penicillin, and 100 µ g/ml streptomycin at 37ºC and 5% CO 2 .
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Co-culture models: HBMEC were plated onto polycarbonate membranes of the upper chamber of the Transwell system (pore size 0.4 µm; Corning Costar, Corning, NY). SVGA, SVGA-Tat, or Jurkat cells were cultured in the lower chamber of the system.
Generation of HIV-1 stock and infection of Jurkat cells
HIV-1 stock was generated using 293T cells (American Type Culture Collection, Manassas, VA). The cells were grown in DMEM containing 10% FBS and antibiotics (100 U/ml penicillin and 100 µ g/ml streptomycin). When the cultures reached ~70% confluence, the cells were transfected with the NL4-3 plasmid containing full-length proviral DNA using calcium phosphate. Following transfection, cells were incubated for 24 h in RPMI 1640 medium with 10% FBS and penicillin plus streptomycin (100 U/ml penicillin, and 100 µ g/ml streptomycin). Then, culture supernatants were collected, filtered through 0.45 µ m filters (Millipore, Bedford, MA) , and frozen at -80°C. HIV-1 p24 levels in the supernatants were determined by ELISA (ZeptoMetrix, Buffalo, NY) as the marker of HIV-1 infection.
HIV-1 stock was used to infect Jurkat T cells. Briefly, 4×10 6 Jurkat cells were cultured in T-25 flasks (Corning Costar) in RPMI 1640 medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 µ g/ml streptomycin. The cells were infected with viral isolate containing 65 ng HIV-1 p24 and incubated at 37°C and 5% CO 2 . The cultures were maintained for up to 18 days with fresh medium added every other day. Non-infected Jurkat cells were used as controls.
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The cells were treated with Aβ(1-40) at the concentrations of 0.1-1 µM for 20 h in EBM-2 medium. HIV-1 Tat strongly binds to serum proteins; therefore, all experiments in co-cultures with SVGA-Tat cells were performed in EGM-2 medium without serum or growth factors.
However, the experiments that involved treatment with Aβ in the presence of HIV-infected
Jurkat cells were performed in cell culture media containing 10% FBS. Cells cultured on chamber slides were treated with 1 µM Aβ(1-40) and SVGA or SVGA-Tat conditioned medium.
In selected experiments, co-culture systems were pretreated for 15 min with 5 µM or 10 µM simvastatin followed by co-treatment with Aβ(1-40) for 20 h. Both simvastatin and Aβ were added to the upper and lower chambers of the Transwell systems. Simvastatin was left in cell culture media for the duration of Aβ treatment. Our preliminary studies (data not shown) indicated that simvastatin concentrations between 5-20 µM did not affect cell viability.
Promoter constructs
Inflammatory gene promoter constructs (pGL3 E-selectin, pGL3 CCL2, and pGL3 IL-6)
were generated based on the pGL3 luciferase basic vector (Promega, Madison, WI). Briefly, 5'-flanking regions of human E-selectin (-1014/+36), CCL2 (-1699/+18), and IL-6 (-1026/+15) This article has not been copyedited and formatted. The final version may differ from this version. To generate the pGL3 LTR construct, 5'-LTR region of HIV-1 was amplified by PCR from the pNL4-3 plasmid and cloned into the pGL3 basic vector. pEGFP LTR construct was a gift from Dr. Avindra Nath (Johns Hopkins University, Baltimore, MD). Promoter-less pEGFP was generated from the pEGFP LTR construct by eliminating the 5'-LTR region. Renilla luciferase pRL-TK control vector was purchased from Promega (Madison, WI).
Transient transfections of HBMEC
HBMEC were cultured on the filter inserts in co-cultures with SVGA, SVGA-Tat, or
Jurkat cells and grown to 90% confluence. To prepare a transfection solution, lipofectin (4 µl/ml) was mixed with Opti-MEM medium (both from Invitrogen, Carlsbad, CA) for 30 min.
Then, 2 µ g/ml of pGL3 E-selectin, pGL3 CCL2, or pGL3 IL-6 promoter constructs was added, followed by incubation for the additional 10 min at room temperature to allow DNA-lipofectin complexes to form.
Filter inserts with HBMEC were removed from the co-culture systems, placed in empty 12 well plates, and washed twice with Opti-MEM to remove serum residues. Then, 250 µl of the This article has not been copyedited and formatted. The final version may differ from this version. transfection solution containing individual promoter gene constructs was added to each filter insert and the cells were incubated for 5 h at 37ºC. Transfection solutions were aspirated and cultures were returned into the Transwell co-culture systems. Cultures were allowed to recover in a normal growth medium for 24 h. Then, the growth medium was replaced with serum free EGM-2 basal medium (for endothelial cells) and DMEM (for astrocytes), and co-cultures were treated with Aβ added into both the upper and lower chambers.
Transient transfections of astrocytes
SVGA cells were transfected using lipofectamin 2000 or lipofectin (both from Invitrogen, Carlsbad, CA). Briefly, SVGA cells were seeded on the 6 well or 24 well plates and grown to ~90% confluence. Prior to transfections, Opti-MEM medium was mixed with lipofectamin 2000
(10 µl/well for the 6 well plates) or lipofectin (1µl/well for the 24 well plates) for 30 min. Then, pEGFP LTR, pEGFP (both 500 ng/well for the 6 well plates), pcDNA3, pcDNA3 Tat86 (2 µ g/well for the 6 well plates or 400 ng/well for the 24 well plates), and pRL-TK (10 ng/well for the 24 well plates) were added to prepare individual transfection solutions. The cells were washed with Opti-MEM, the specific transfection mixtures were added to each well, and transfections were performed for 4 h at 37ºC. Then, cultures were washed and allowed to recover in growth medium for 20 h. Astrocytes transfected with the EGFP constructs were imaged using an inverted fluorescence microscope. In cultures transfected with other constructs, luciferase activity was determined as described below.
Luciferase activity assay
This article has not been copyedited and formatted. The final version may differ from this version. to the Eppendorf tubes and centrifuged to remove cell debris. Then, 10 µl of the cell extracts were mixed with 100 µl luciferase assay reagent containing luciferin plus ATP and luminescence was measured in a luminometer with dual automatic injector (Turner Designs, Sunnyvale, CA).
The samples were then mixed with the Stop and Glo reagent and renilla luciferase activity was determined as an internal control.
All transfection results from astrocytes were expressed as the ratio of the firefly to renilla luciferase activity. On the other hand, Aβ used for treatment of HBMEC interfered with the renilla luciferase assay. Therefore, firefly luciferase activity in HBMEC was normalized to total protein levels and the transfection results were expressed as relative light units (RLU)/µg protein.
Immunofluorescence microscopy
HBMEC cultured on Permanox chambered plastic slides were fixed with ethanol for 30 min at 4 o C. After washing with PBS and blocking with 3% bovine serum albumin in PBS for 30 min, samples were incubated overnight at 4˚C with rabbit polyclonal anti-E-selectin antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The excess of primary antibody was removed, slides were washed with PBS, and incubated with Texas Red-conjugated secondary antibody (Santa Cruz Biotechnology) for 2 h at room temperature. After washing with PBS, slides were mounted using ProLong Gold Antifade reagent containing 4',6-diamidino-2-phenylindole (DAPI, Invitrogen, Carlsbad, CA) to visualize the nuclei. Specimens were covered with coverslips and This article has not been copyedited and formatted. The final version may differ from this version. 12 evaluated under an epifluorescence Nicon Eclipse E600 microscope. The images were captured using a Spot CCD camera system.
Enzyme-Linked Immunosorbent Assay (ELISA)
Concentrations of CCL-2 and IL-6 were quantified using commercially available human CCL-2 and IL-6 Immunoassay kits (R&D Systems, Minneapolis, MN). Assays were performed using aliquots of cell culture media collected from both the luminal and abluminal chambers of the Transwell co-culture systems.
Statistical Analysis
Data were analyzed using SigmaStat 2.0 (SPSS Inc., Chicago, IL, USA). One-or twoway ANOVA was used to compare responses among treatments. Treatment means were compared using Bonferroni's least significant procedure and p<0.05 was considered significant.
RESULTS
Morphological characterization of HBMEC and SVGA-Tat cells
HIV-1 can infect astrocytes, which then produce viral proteins such as Tat. Astrocytes constitute the most abundant cell type in the brain and viral proteins produced by infected astrocytes are likely to have significant neuropathological effects. Therefore, the present study was based on co-culture systems of HBMEC with astrocytes expressing HIV Tat protein (SVGA-Tat cells) or normal SVGA cells used as controls.
Tat expression by SVGA-Tat astrocytes
In order to confirm expression and activity of Tat protein in our culture systems, SVGATat and control SVGA astrocytes were transfected with pEGFP LTR ( HBMEC co-cultured with SVGA-Tat or control SVGA cells were transfected with the firefly luciferase reporter constructs containing human E-selectin, CCL2, or IL-6 promoter sequence.
Then, both HBMEC and astrocytes were exposed to 0.1, 0.5, or 1 µM Aβ(1-40) for 20 h. In cocultures of HBMEC with control SVGA cells, Aβ induced a marked increase in the promoter activity of E-selectin ( Figure 3A ) and CCL2 ( Figure 3B) ; however, it did not affect promoter activity of IL-6 ( Figure 3C ). On the other hand, exposure to Aβ in co-cultures with SVGA-Tat cells markedly amplified promoter activities of all studied proinflammatory genes ( Figures 3A-3C ). These effects were achieved by 1 µM Aβ for E-selectin and IL-6 promoters, and by 0.5 µM Aβ for CCL2 promoter.
To verify the specificity of the Aβ(1-40) effects, co-cultures were also exposed to the reversed sequence Aβ peptide (Aβ40-1) at the concentration of 1 µM. As illustrated in Figures   3A-3C , Aβ(40-1) did not affect transactivation of the inflammatory gene promoters.
In addition to promoter activities, we determined the effects of Aβ and/or SVGA-Tat on protein levels of E-selectin, CCL2, and IL-6 (Figures 4A-4C) . 
Simvastatin protects against Tat and Aβ-induced stimulation of promoter activities of proinflammatory genes in HBMEC
Statins have been demonstrated to have pleiotropic effects, including anti-inflammatory and anti-HIV properties. Therefore, we hypothesized that they can protect against Tat and Aβ-induced proinflammatory effects. To address this hypothesis, HBMEC were co-cultured with SVGA-Tat or control SVGA cells and transfected with the pGL3 E-selectin, pGL3 CCL2, or pGL3 IL-6 construct. Then, the co-cultures were pretreated for 15 min with 10 µM (Figures 5A and 5B) or 5 µM ( Figure 5C ( Figure 5C ) promoter activities. Treatment with simvastatin upregulated the IL-6 promoter activity in control (i.e., not exposed to Aβ) co-cultures of HBMEC with SVGA-Tat cells.
Nevertheless, simvastatin effectively protected against upregulation of E-selectin and IL-6
This article has not been copyedited and formatted. The final version may differ from this version. promoters in co-cultures of HBMEC with SVGA-Tat and exposed to Aβ. Inhibition of IL-6 promoter activity was achieved by 5 µM simvastatin; however, 10 µM simvastatin was required to block E-selectin promoter activity.
Aβ amplifies HIV-1-stimulated transactivation of E-selectin promoter in HBMEC
In the final series of experiments, we investigated whether exposure to Aβ can stimulate E-selectin promoter activity in the presence of HIV-1. HBMEC were transfected with the pGL3 E-selectin construct and co-cultured with HIV-1-infected or control Jurkat cells for 24 h.
Cultures were then pretreated for 15 min with 10 µ M simvastatin or vehicle control and exposed 
DISCUSSION
The mechanisms of HIV entry into the brain are still unclear; however, they may occur through the so-called Trojan horse mechanism, via HIV-infected monocytes crossing the BBB (Gartner, 2000) . Thus, induction of inflammatory reactions which mediate monocyte adhesion This article has not been copyedited and formatted. The final version may differ from this version. to the brain endothelium and transendothelial migration are of particular significance. Therefore, in the present studies we focused on expression of inflammatory mediators, such as E-selectin (an adhesion molecule), CCL2 (a chemokine), and IL-6 (an inflammatory cytokine) in brain endothelial cells. Upregulation of these inflammatory mediators can induce alterations of the BBB integrity by facilitating adhesion and migration of leukocytes into the brain (for review see Buckner et al., 2006) . The present study was based on co-culture systems in which HBMEC were exposed to Tat produced by transfected astrocytes. Such co-cultures are clinically relevant, because HIV can infect astrocytes, which then are able to produce viral proteins, such as Tat.
Astrocytes along with HBMEC are the structural and functional part of the BBB. In addition, astrocytes are susceptible to Aβ treatment and can influence HBMEC inflammatory responses.
Indeed, we observed that Aβ stimulated E-selectin promoter activity in HBMEC co-cultured with SVGA astrocytes (Figure 3A) but not with Jurkat cells (Figure 6 ).
The facts that a) deposits of Aβ increase in normal aging (Price and Morris, 1999) , b) Aβ can induce vascular alterations (Deane and Zlokovic, 2007) , and c) Aβ may be involved in HIVassociated pathology (Wojtowicz et al., 2002) , prompted us to study the hypothesis that Aβ and Tat may cross-potentiate their toxic effects and alter the functions of the BBB. Indeed, the results of the present study indicated that co-exposure to Aβ(1-40) and Tat or HIV-1 infected cells can synergistically elevate promoter activity of E-selectin, CCL2, and IL-6. These effects were also confirmed at the protein levels (Figure 4) . Although the proinflammatory influence of Tat and Aβ in endothelial cells has been recognized , the evidence that these factors can exert synergistic proinflammatory effects is the new finding of the present study.
This article has not been copyedited and formatted. The final version may differ from this version. As illustrated in Figure 3 , exposure to Aβ resulted in a dose-dependent increase in promoter activities of E-selectin and IL-6. On the other hand, CCL2 promoter was activated by
Aβ at the concentration of 0.1 and 0.5 µ M but not at 1 µ M. Although Aβ is generally considered a pro-oxidative factor, evidence indicates that Aβ-mediated regulation of cellular oxidation may depend on the ratio of Aβ to other prooxidative factors. Indeed, prooxidative/antioxidative effects of Aβ can be regulated by the molar ratio of Aβ to Cu2+. When Cu2+ is bound to two molar equivalents of Aβ, lipid peroxidation is inhibited and Aβ exerts antioxidant effects (Hayashi et al., 2007) . Thus, it is possible that these finely tuned regulations of cellular redox balance might be responsible for the lack of CCL2 stimulation by 1 µ M Aβ.
The transfection experiments with the promoter constructs performed in the present study indicate that induction of inflammatory genes by Aβ, Tat, or HIV-1 occurs primarily at the transcriptional levels. In agreement with these results, it has been shown that Tat-induced expression of TNF-α is regulated by an NF-κB-dependent pathway in macrophages and astrocytes (Chen et al., 1997) . The NF-κB-dependent pathway is also involved in Tat-induced upregulation of IL-6 and IL-8 expression in human breast cancer cells . In addition, treatment with Tat can induce DNA binding activities of other transcription factors, such as CREB and AP-1, which are known to regulate inflammatory responses (Kumar et al., 1998; Toborek et al., 2005) . chemokines (MIP-1β, CCL-2 and IL-8) in monocytes . Transcription factor C/EBPdelta was also shown to be involved in Aβ-mediated induction of IL-6 and CCL-2 (Hu et al., 2000) . Thus, Tat and Aβ-mediated stimulation of a variety of transcription factors may be responsible for cross-potentiation of inflammatory responses as observed in our study.
Another important finding was that treatment with statins, such as simvastatin, protected against Aβ and Tat or HIV-1-induced inflammatory responses. Statins are drugs which effectively diminish cholesterol biosynthesis by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. In HIV-infected patients, statins have been successfully introduced to improve disturbances in lipid profile (Dube et al., 2003) . On the other hand, statins, such as simvastatin can also increase NF-κB activation and superoxide production via heme oxygenase-1-dependent mechanism (Hsieh et al., 2007) . Such effects could be responsible for an increase in IL-6 promoter activity observed in simvastatin-treated HBMEC in the presence of SVGA-Tat cells.
Observed in the present study, the protective effects of simvastatin on Tat and Aβ-induced inflammatory responses are supported by literature reports. For example, it was shown that statins downregulated VCAM-1, E-selectin, IL-6, IL-8, CCL-2 expression, and had immunomodulatory effects in endothelial cells (for review see Greenwood et al., 2006) . In monocytes, statins inhibited adhesion and migration (Pozo et al., 2006) . Statins also decreased inflammatory responses in microglia and attenuated experimental autoimmune encephalomyelitis (Nath et al., 2004) . Anti-inflammatory properties of statins appear to be related to decreased synthesis of several isoprenoid intermediates, which normally are involved in post-translational modification of proteins, including the γ -subunit of heterotrimeric G-proteins and Ras and Rho proteins (Liao, 2005) . Isoprenylation of Ras and Rho is required for covalent attachment, subcellular This article has not been copyedited and formatted. The final version may differ from this version. (Liao, 2005) .
In the present study, simvastatin not only protected against Tat and Aβ-induced inflammatory reactions, but also was highly effective against HIV-mediated stimulation of Eselectin promoter transactivation. The protective effects suggest that statins may be a valuable group of drugs for supplemental therapy in HIV infection. Indeed, a short-term statin treatment was demonstrated to decrease HIV-1 viral load in patients and inhibit HIV-1 infection through downregulation of Rho activity (del Real et al., 2004) . However, these effects were not confirmed in another study in which no anti-HIV activity of statins was observed in cell culture or in HIV-positive patients (Moncunill et al., 2005) . It also should be noted that most statins are metabolized through the CYP3A4 pathway, which is inhibited by protease inhibitors widely used in anti-retroviral therapy. Thus, interactions between statins and protease inhibitors may result in an increase in tissue statin concentrations, leading to drug toxicity. On the other hand, statins such as pravastatin and fluvastatin are the least influenced by the CYP3A4 pathway and, therefore, might be safer when administered with protease inhibitors (Dube et al., 2003) .
Evidence also indicates that statins may provide useful treatment in pathologies related to
Aβ pathology, such as AD dementia. Retrospective epidemiological studies revealed that patients with high cholesterol levels and treated with statins less frequently developed AD (Jick et al., 2000) . A relative safety of simvastatin was demonstrated in a 5 year clinical study (Pedersen et al., 1996) , suggesting that statins might be safely used to prevent the development of AD. The beneficial effects of statins were also shown in patients with mild to moderate AD (Sparks et al., 2006) . Finally, experimental studies revealed that statins can protect neurons This article has not been copyedited and formatted. The final version may differ from this version. (Fassbender et al., 2001; Li et al., 2006) . However, there are also reports which do not support these findings or even suggest that statins can induce cognitive impairment (Padala et al., 2006) . Thus, to elucidate these controversies, at least two large multicenter trials have been initiated using simvastatin and atorvastatin (Miida et al., 2005) in an attempt to better understand the effects of statin therapy on dementia.
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